A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

New Category III CPT Code for TherOx SSO2 Therapy (ZOLL Medical)

New Category III CPT Code for TherOx SSO2

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the American Medical Association (AMA) CPT Editorial Panel issued a new Category III CPT® code for herOx SSO2, became effective July 1, 2021, for its TherOx® SuperSaturated Oxygen (SSO2) Therapy.

 

The code, 0659T (transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance [e.g., fluoroscopy], angiography, and radiologic supervision and interpretation), is effective July 1, 2021 for SSO2 Therapy including treatment of patients with left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attacks. SSO2 Therapy is the first and only FDA-approved treatment that has been clinically proven to significantly reduce cardiac muscle damage in heart attack patients after coronary angioplasty with stenting.1

SSO2 Therapy is indicated for patients who suffer LAD STEMI — also known as “widowmaker” heart attacks due to the high mortality rate — and are treated within six hours of symptom onset. The therapy delivers high levels of dissolved oxygen at 7–10 times the normal amount directly to the damaged heart muscle immediately after the coronary artery has been successfully opened via angioplasty and stenting. Multiple clinical trials have demonstrated the efficacy of SSO2 Therapy to reduce infarct size.1,2,3

The New Category III CPT Code for TherOx SSO2 Therapy  was supported by the leadership of the Society for Cardiac Angiography and Interventions (SCAI) and the American College of Cardiology (ACC). The decision was based on a review of published, peer-reviewed literature, the need for an accurate national code for physicians to use in reporting SSO2, and the importance of SSO2 as an emerging, innovative technology.

“The AMA issuing a CPT code for TherOx’s SSO2 Therapy is a significant milestone for the millions of patients who could benefit from its use,” commented Neil Johnston, President of ZOLL Circulation. “More and more hospitals are adopting this therapy to treat patients with the most serious form of heart attacks, and now the Category III code provides another major step forward toward capturing data on SSO2 and demonstrating improved patient outcomes.”

CPT codes are granted by the AMA CPT Editorial Panel and are widely used by government payers, including Medicare and Medicaid, and commercial health plans to process claims and determine reimbursement for healthcare services and procedures.

SSO2 Therapy was developed by Irvine, California-based TherOx, Inc., now part of ZOLL Medical Corporation.

Other Zoll Medical news of interest here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy